Aspen Neuroscience and Bambusa Therapeutics have set terms for their initial public offerings, with each company seeking to raise $150.0 million at the midpoint of its proposed range. Both plan to offer 9.375 million shares at $15.00 to $17.00 per share and have applied to list on Nasdaq. San Diego-based Aspen Neuroscience, which is developing a personalized cell therapy for Parkinson’s disease, plans to trade under ASPE. Boston-based Bambusa Therapeutics, which is developing antibody treatments for inflammatory and immunological diseases, plans to trade under BBTX.
Aspen Neuroscience is developing therapies for neurodegenerative diseases using cells derived from a patient’s own tissue. Its lead candidate, sasineprocel, is an investigational cell therapy being studied for Parkinson’s disease. The approach begins with a skin biopsy: the patient’s cells are reprogrammed into stem cells and then developed into dopamine-producing neurons intended for implantation in the brain.
The goal is to replace dopamine-producing neurons that have been lost as Parkinson’s progresses. The treatment is being evaluated as a one-time procedure, though its safety, effectiveness and durability remain under investigation.
Aspen is evaluating sasineprocel in its Phase 1/2a ASPIRO trial. As of the August 18, 2026 data cutoff, 15 patients had received the treatment, and the company reported that it was generally well tolerated, with most reported adverse events described as mild to moderate. The study is open-label, meaning patients and researchers know which treatment is being administered. Results from a small, early-stage study may not predict outcomes in a larger trial.
Following feedback from the FDA, Aspen expects to begin dosing patients in a Phase 3 trial in the second half of 2027. The company plans to use what it learns from ASPIRO—including information on dosing, surgical techniques and delivery procedures—to help inform the later-stage trial.
Aspen also intends to use its cell-therapy platform to pursue other neurodegenerative conditions. Its more advanced focus, however, remains sasineprocel, making progress in Parkinson’s disease especially important to the company’s near-term outlook.
At the $16.00 midpoint, Aspen’s offering would value the company at approximately $465.3 million, based on the 29.1 million shares expected to be outstanding after the offering. Leerink Partners, UBS Investment Bank, Piper Sandler, Stifel and Oppenheimer & Co. are the underwriters.
Like many clinical-stage biotechs, Aspen has incurred substantial losses and expects to continue spending heavily on development. It reported a $62.1 million net loss in 2025 and a $36.5 million net loss in the first half of 2026. The company held approximately $72.4 million in cash, cash equivalents and marketable securities as of June 30, 2026. Proceeds from the IPO are intended to support sasineprocel’s clinical development, other research and development, and general corporate purposes.
For investors, Aspen’s opportunity rests on whether its patient-specific therapy can demonstrate meaningful and durable benefits in larger studies. The personalized manufacturing process and surgical delivery also present challenges that will need to be addressed as the program advances.
Bambusa Therapeutics is developing bispecific antibodies designed to target two disease pathways in a single treatment. The company is focused on immunology and inflammation, with programs aimed at conditions affecting the skin, respiratory system and gastrointestinal tract. Its approach is designed to produce longer-acting therapies that could be administered less frequently, although those potential benefits have yet to be established in later-stage trials.
Its lead candidate, BBT001, is being studied for moderate-to-severe atopic dermatitis, commonly known as eczema, and chronic spontaneous urticaria, a condition characterized by recurring hives. The drug targets two pathways associated with inflammation and itch: IL-4 receptor alpha and IL-31.
In July 2026, Bambusa reported preliminary results from a small proof-of-concept study of BBT001 in patients with moderate-to-severe atopic dermatitis who had not previously received certain biologic treatments or JAK inhibitors. All 17 enrolled patients were evaluable for preliminary safety and clinical response. The company reported improvements in eczema severity and itch and said the treatment was observed to be well tolerated. The early results are encouraging, but the small study and limited follow-up mean additional data will be needed to assess the treatment’s effectiveness and safety.
Bambusa expects several additional BBT001 data readouts in the first half of 2027, including results from longer studies in atopic dermatitis and a study in chronic spontaneous urticaria. It also plans to begin start-up activities for a Phase 2b atopic dermatitis trial of an injectable formulation by the end of 2026.
The company’s second lead candidate, BBT002, targets IL-4 receptor alpha and IL-5 and is being developed for respiratory and allergic diseases. Bambusa is studying the drug in conditions including chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps and asthma. It expects initial patient data from COPD and nasal-polyp studies in the first half of 2027. Two additional candidates, BBT003 and BBT004, remain in preclinical development.
At the $16.00 midpoint, Bambusa’s proposed offering would value the company at approximately $796.2 million, based on 49.8 million shares expected to be outstanding after the IPO. BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are underwriting the offering.
Bambusa reported a $41.1 million net loss in 2025 and a $22.4 million net loss in the first half of 2026, compared with a $14.7 million loss in the first half of 2025. The company held $71.5 million in cash, cash equivalents and marketable securities as of June 30, 2026.
Bambusa expects its existing resources and IPO proceeds to fund operations into late 2028, based on its current plans. The company cautions that the proceeds will not be sufficient to carry all of its candidates through regulatory approval and that it will need additional capital.
The two offerings give investors exposure to distinct areas of biotechnology. Aspen is focused on a personalized cell therapy for Parkinson’s disease, while Bambusa is building a broader pipeline of antibody treatments for inflammatory conditions. Both companies have candidates in clinical development, but neither has an approved product, and both face the uncertainty and expense of further trials.
For Aspen, the progression of sasineprocel toward a Phase 3 study will be central. For Bambusa, a series of expected clinical readouts in the first half of 2027 could help investors assess whether its early findings hold up as development advances.